PSA levels in trans and non-binary people with a prostate
Part of Cancer, Kidney & urinary clinical trials.
This study aims to find normal PSA (prostate-specific antigen) levels for trans and non-binary people who have a prostate and are on hormone therapy or have had certain surgeries. Your participation could help improve future cancer screening guidelines for your community.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are over 40 years old
- You are transgender or non-binary (your gender is different from the one assigned at birth)
- You still have your prostate
- You have been taking estradiol or anti-androgens for at least 3 months, or have had your testicles removed (orchidectomy) at any time
- You are eligible for NHS care
- You have never had prostate cancer, prostate surgery, or prostate radiotherapy
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study collects and measures “biomarkers” (measurable signs in the body) from people with prostate cancer who are about to have surgery or radiation. The goal is to understand how prostate cancer behaves during treatment, which may help improve care in the future.
This study looks at how a prostate-specific scan marker (PSMA) changes after you start or continue hormone therapy. It may help doctors better understand who responds and how quickly prostate cancer biology shifts during treatment.
This study looks at how PSA (a blood marker) levels measured shortly after prostate removal surgery can predict whether cancer comes back. Researchers hope this helps doctors identify patients who may need closer monitoring or additional treatment after surgery.
This trial studies whether testosterone levels before and around radical prostate surgery affect cancer control and sexual/physical recovery. It may help doctors understand who benefits from testosterone replacement and who should not.
This study checks whether certain blood markers can help predict how well people with prostate cancer will respond to therapy. It may help doctors choose the most effective treatment sooner by using information from your blood.
This study tests a tailored (personalized) radiation plan for men whose PSA (“prostate blood test”) rises after prostate surgery but who have no detectable spread on scans. It may help control cancer growth by targeting the right area based on your situation.
Hear when a new Prostate CA trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.